O rthotopic heart transplantation (OHT) remains the most effective therapy for end-stage heart failure (HF), with median survival rates that exceed 11 years. 1 Despite improving outcomes, the overall effect of transplantation is limited by the significant shortage of suitable donor hearts. Each year in the United States, ≈2200 patients with advanced HF undergo cardiac transplantation, whereas ≈150 000 patients may be in need of advanced therapies such as OHT. 2 As a result, transplantation is typically limited to a highly select patient population that is younger with a lower burden of comorbid illness. Conversely, the growing population of patients with advanced age and end-stage HF are often thought to be at high risk for complications after OHT and excluded from transplant listing.
Clinical Perspective on p 1238
Several US transplant centers have developed formal extended criteria cardiac transplantation (ECCT) strategies. The underlying premise of ECCT is to match patients who fall outside traditional listing criteria because of advanced age or comorbid illness with donors or donor organs that have highrisk features. Previous analyses of ECCT outcomes have demonstrated shortened mean survival with ECCT compared with standard criteria cardiac transplantation (SCCT). 3 However, post-transplant survival in this cohort is superior to that anticipated with ongoing medical management with advanced systolic HF. [4] [5] [6] [7] [8] [9] [10] A previous study at our center confirmed these acceptable outcomes and also demonstrated similar post-transplant morbidity for patients undergoing ECCT and SCCT. 3 With median OHT survival now extending beyond 10 years, re-examination of intermediate and long-term outcomes after ECCT is warranted. Furthermore, with the necessity of lifelong immunosuppression using nephrotoxic agents, ascertaining the long-term effect of ECCT on renal function is clinically important. The purpose of this study is to describe our experience with ECCT during the past 10 years by comparing outcomes with ECCT and SCCT, to understand factors that influence survival, and to examine the effect of renal dysfunction in the ECCT population.
Methods
An extended-criteria protocol was developed and initiated at our center in January 2000. Patients were considered for ECCT if they were aged ≥65 years or they had significant comorbidities including significant renal insufficiency, peripheral arterial disease (including carotid artery disease), or poorly controlled diabetes mellitus. Cytomegalovirus seropositivity is not considered a risk factor for consideration of SCCT or ECCT. ECCT patients signed informed consent for the transplant team to use organs that may be deemed unsuitable for use in SCCT recipients. Unfavorable characteristics of these hearts included older donors, single vessel coronary artery disease, left ventricular (LV) hypertrophy, LV dysfunction, high-dose inotropic support, or donors considered high risk by the United Network for Organ Sharing (UNOS). Pediatric patients (<18 years of age), patients receiving multiorgan transplants, and patients undergoing retransplantation were excluded from this analysis.
Data were abstracted from the medical record by retrospective chart review. Recipient baseline characteristics were obtained including demographics, cause of cardiomyopathy, pretransplant mechanical circulatory support, laboratory values, and UNOS listing at the time of OHT. Donor data were collected from the UNOS database. Variables extracted included ischemic time, donor age, LV ejection fraction, LV posterior wall thickness, septal wall thickness, the number of inotrope medications at the time of organ procurement, and UNOS classification of the donor as high risk (suggesting a potential for disease transmission from donor to recipient). The sequence number at which the donor organ was accepted by our center for a suitable recipient was also extracted in addition to the length of donor downtime (presumed or observed pulselessness) and need for cardiopulmonary resuscitation.
End Point Definitions
The primary end point for this study was all-cause mortality. Predefined short-, intermediate-, and long-term outcomes were defined as measures of post-transplant morbidity. Short-term outcomes at 1 year post-OHT included cellular rejection episodes (International Society for Heart and Lung Transplantation grade ≥2R/3A cellular rejection), rehospitalization for any cause, presence of cardiac allograft vasculopathy (defined as a ≥75% lesion in any epicardial coronary artery by angiography), renal function measured by serum creatinine (Cr) and estimated glomerular filtration rate (calculated using the Modification of Diet in Renal Disease formula), and chronic kidney disease (CKD) stage. We do not routinely screen for antibody-mediated/humoral rejection, and these data were not extracted. Intermediate-term (5-year) outcomes included presence of cardiac allograft vasculopathy and renal function.
Statistical Methods
Continuous variables are expressed as the median (25th-75th percentiles); categorical variables are expressed as number and percentage. Continuous and ordinal variables were compared using the Wilcoxon rank-sum test, and categorical variables were compared using the Pearson χ 2 test or exact test when appropriate. Kaplan-Meier methods were used to estimate survival in both ECCT and SCCT groups, and a Cox proportional hazards model compared time with mortality by listing criteria. A multivariate Cox proportional hazards model was constructed using available baseline clinical characteristics to determine the effect of these variables on post-transplant survival. Incremental risk associated with assignment to the ECCT list was determined by a second Cox proportional model that included listing criteria. Proportional hazards and linearity assumptions were checked for all models, and transformations applied when necessary. Adjusted survival curves by listing criteria were estimated using the corrected group prognosis method. 11 Nonmortality post-transplant outcomes including renal function, presence of cardiac allograft vasculopathy, cellular rejection episodes, and rehospitalization are described using the median (25th-75th percentiles) or percentage. All analyses were conducted using SAS statistical software version 9 (SAS Inc, Cary, NC). A P value <0.05 was considered statistically significant. The study protocol was approved by the Institutional Review Board at Duke University Medical Center.
Results
From January 1, 2000, to December 31, 2009, 454 patients qualified for inclusion and underwent primary cardiac transplantation at our institution. We identified 84 ECCT patients (age range, 43-75 years) and 370 SCCT patients (age range, 18-68 years). Baseline characteristics are described in Table 1 . ECCT patients were significantly older (66.6 versus 53.2 years; P<0.001) than SCCT patients and a greater proportion were white, had a history of diabetes mellitus, and had ischemic cardiomyopathy. Although the proportion of SCCT patients supported with pretransplant LV assist device (LVAD) was greater than that of the ECCT patients, there was no significant difference in the proportion of patients supported with an intra-aortic balloon pump at the time of cardiac transplantation.
Donor Data
ECCT donors were older (39.5 versus 33.0 years; P<0.001), and the median cold ischemic time was longer (3.7 versus 3.4 hours; P<0.001) than in SCCT. The number of donors older than 35 years was significantly higher in the ECCT group (71% versus 47%; P<0.001), and 38% of the donors for ECCT were >45 years of age (P=0.06 compared with SCCT). Data were available on the majority of donors, but as shown in Table 2 , certain data elements were not available in the UNOS data files. Donor LV ejection fraction and number of inotrope medications administered were similar between the cohorts. Furthermore, there was no difference in the proportion of donors classified as UNOS high risk or the proportion of donors who were reported to have cardiac arrest requiring cardiopulmonary resuscitation or downtime before cardiopulmonary resuscitation was initiated ( Table 2 ). The cause of death was not different between ECCT and SCCT donors, but the median sequence number for the ECCT group recipients was higher than the SCCT group (27 versus 6; P<0.001).
Unadjusted Survival
Unadjusted Kaplan-Meier survival estimates at 1 and 5 years were 90% and 78% for SCCT patients and 82% and 58% for ECCT patients (Figure 1 ). By univariate analysis, ECCT was associated with a 2-fold risk for increased mortality (hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.42-3.03; P<0.001).
Risk Factor Analysis
To identify recipient factors that influence survival after OHT, multivariate analysis was performed using the following candidate variables: age, race, sex, presence of VAD, presence of intra-aortic balloon pump, ischemic cardiomyopathy, baseline Cr, and UNOS status at time of transplant. After adjusting for all other variables, only increasing age >50 (HR, 1.04 per year; 95% CI, 1.01-1.07; P=0.014) and Cr (HR, 1.05 per 0.1 mg/dL increase; 95% CI, 1.02-1.09; P=0.001) were significant predictors of mortality (Table 3 ). Other parameters that showed a trend toward reduced survival included black race, female sex, and ischemic cardiomyopathy (P=0.051, P=0.056, and P=0.051, respectively; Table 3 ).
Adjusted Survival
A second Cox proportional hazards model was created to incorporate recipient variables affecting survival (from Model 1) with the use of ECCT donors. In this model, ECCT listing and Cr were associated with survival (Table 4 ). After adjustment for baseline characteristics, ECCT was associated with increased risk of mortality (HR, 1.62; 95% CI, 1.02-2.58; P=0.042), and SCCT survival was higher than ECCT at 1 (89% versus 86%) and 5 years (77% versus 66%). Increased Cr (HR, 1.05 per 0.1 mg/DL; 95% CI, 1.02-1.09; P=0.001) was also significantly associated with increased risk of posttransplant mortality after adjusting for other variables, including transplant listing status. Adjusted survival curves are shown in Figure 2 .
Major Morbidity
There were no differences between ECCT and SCCT in the index length of stay or number of acute allograft rejection episodes during the first year (Table 5 ). A greater proportion of patients in the ECCT group were hospitalized ≥2× during the first year. At 5 years after transplant, the median estimated glomerular filtration rate of SCCT patients was 42.8 mL/ min per m 2 compared with 37.1 mL/min per m 2 in the ECCT cohort. The median serum Cr in the SCCT and ECCT groups was 1.70 mg/dL and 1.90 mg/dL, respectively. When classified into CKD stages, 75.6% and 88.2% of SCCT and ECCT had CKD stage 3 or more at 1 year post-OHT, whereas 81.0% and 100% of SCCT and ECCT patients alive at 5 years after transplantation developed CKD ≥3 (Table 5 ). In addition, 4.1% of SCCT and 9.4% of ECCT patients alive at 5 years after transplant required permanent hemodialysis ( Table 5 ).
Discussion
The concept underlying our ECCT program is to transplant carefully selected patients who fall outside traditional listing criteria using organs that are commonly not used because of older donor age, UNOS high risk classification, or an imperfection in the donor heart. The current analysis extends a previous analysis of this program with incorporation of data from an additional 34 ECCT patients transplanted between 2006 and 2010 and with long-term follow-up of the entire cohort. 3 We show that ECCT patients have significantly lower riskadjusted survival at both 1 and 5 years compared with SCCT. However, it seems that ECCT survival remains superior to that of a similarly ill patient population treated medically, 5, 12 particularly patients requiring inotropic support. This riskbenefit ratio is less well defined for the 36% of patients in our ECCT cohort that were listed as UNOS 2 at the time of transplant; however, accurate estimates of mortality in ambulatory advanced HF are lacking. In a recent collaborative study from 3 transplant centers, 1-year estimated survival using the Seattle Heart Failure Model for UNOS 2 recipients was 89% at the time of transplant. 13 However, the mean age of those in this analysis was 53 years (similar to our SCCT cohort), and the majority of high-risk patients required urgent rather than elective transplantation. Thus it seems likely that older UNOS 2 patients remain at high risk for death or need for urgent transplantation. Our survival data are also consistent with reported 1-year survival rates after ECCT from other high volume centers (78%-83%) 6, 14 and suggests that ECCT remains an important strategy for the management of end-stage HF. Moreover, given the increasing lifespan of patients undergoing OHT in the current era, our study highlights important clinical characteristics such as recipient age and renal function that are associated with long-term outcomes after ECCT.
Our analysis demonstrates the importance of carefully evaluating recipient factors when selecting patients for ECCT. Decreased ECCT survival may not be unexpected, given the ECCT cohort was older, with a greater burden of comorbidities including diabetes mellitus and renal dysfunction. The mean age at transplantation of our ECCT cohort was 66 years compared with 53 years in the SCCT cohort. Recipient age >50 years was an important predictor for post-transplant survival in the overall cohort, which remained predictive in a multivariate model. When listing criteria was used as a covariate (Model 2), age was no longer predictive for post-transplant survival, reflecting our practice of assigning older patients to ECCT. Careful selection of older ECCT candidates is also reflected in the severity of illness before transplant. We observed that a greater proportion of ECCT patients were transplanted as UNOS status 2 and fewer were supported with a VAD at the time of transplantation. Our general approach has been to use durable mechanical circulatory support as destination therapy in hemodynamically unstable patients, thus leaving the ambulatory, medically treated advanced HF population for ECCT. This strategy has allowed us to treat older patients with advanced therapies without progression of end-organ dysfunction, which might become preclusive while awaiting a suitable organ. Existing end-organ dysfunction and other chronic underlying conditions are important contributors of the differences seen in post-transplant outcomes with ECCT. Previous work has demonstrated that renal function is a major risk factor for decreased survival after cardiac transplantation. 1, 15 Baseline renal function has been identified as an important risk factor for post-transplant survival in a recently published recipient risk score. 16 In transplant recipients over the age of 65 years, lower Cr was associated with improved 5-year survival in recipients. 17 In the current analysis, we show that baseline renal function is a potent predictive factor for patients undergoing OHT with each 0.1 mg/dL increase in serum Cr associated with a 5% increase in mortality (Table 4 ). In addition to the association with survival, post-transplant renal dysfunction was more prominent in the ECCT group. Of patients who are alive and followed up for 5 years, the proportion with stage 3 or more CKD was 81.0% and 100% for SCCT and ECCT, respectively. Of patients who are followed up for 5 years, 4.1% of SCCT and 9.4% of ECCT patients developed end-stage renal disease requiring permanent hemodialysis. The increased proportion in the ECCT group can be attributed to worse baseline renal function and a higher proportion of subjects with diabetes mellitus at the time of transplant. Furthermore, the adverse effect of immunosuppression may be greater in this older cohort whose renal impairment is underestimated by using serum Cr alone. 16 Another important outcome that was different between the 2 groups was the rate of rehospitalization during the first year after transplant. Our group has previously shown that the rate of rehospitalizations was significantly higher in ECCT. 3 In the current analysis, we confirm the higher rate of rehospitalizations with the larger ECCT cohort. A greater proportion of ECCT patients required admission after transplantation (64.3% ECCT, 52% SCCT). Common causes for post-OHT hospitalizations include acute allograft rejection, infection, complications of cardiac allograft vasculopathy, renal failure, and malignancy. 1 We did not find any differences between the 2 groups for rejection episodes or the development of cardiac allograft vasculopathy, but previous work did not demonstrate differences in cytomegalovirus infection rates. 3 Typically ECCT programs use donor organs considered unacceptable for SCCT. Our ECCT program uses cardiac allografts from older donors, but the majority of organs did not show evidence of diminished ejection fraction or high inotropic support requirements ( Table 2) . Ischemic time in the ECCT group was significantly longer, reflecting our willingness to use organs declined for recipients in neighboring UNOS regions (we do not select organs with an anticipated ischemic time >4 hours). This is supported further by the higher median sequence number of the donors used in the ECCT group, which reflects the use of organs from outside our local region or high-risk features of the donor/organ not captured by the UNOS data. Both donor age and ischemic time are associated with increased risk of death after transplant particularly within the first year after transplant. 16 This increased risk is often because of primary graft dysfunction 18 defined broadly as severe uni-or biventricular dysfunction severe enough to not meet the circulatory requirements of the recipient ≤24 hours of cardiac transplantation. Thus the delayed (>1 year) mortality associated with ECCT is more likely related to recipient factors including age and renal dysfunction rather than impaired donor organ quality. 19 Implicit in this finding is our acknowledgment of the likely interaction between donor age and ischemic time and their combined effect on shortterm outcomes. Although we have no predefined upper limit for donor age, we are unlikely to select an older donor with an anticipated ischemic time that is also prolonged to avoid the risk of primary graft dysfunction and early mortality.
The cause of death for the majority of patients transplanted at an advanced age is typically unrelated to allograft function. Of 11 ECCT patient deaths from our group's previous work, only 1 was because of rejection and 1 was potentially related to the function of the allograft. 3 Another study of 62 ECCT patients with a 2-year survival of 68% reported 21 deaths over a median follow-up of 3.25 years. Seven of 21 deaths occurred ≥1 year after transplant; none of these deaths resulted from graft failure or rejection. 6 In a large study examining the outcomes of marginal donors from the UNOS registry, infection, but not primary graft dysfunction or rejection, was a leading cause of morbidity and mortality both at 1 year and 5 years after transplantation. 20 Furthermore, a composite report from the International Society for Heart and Lung Transplantation shows that graft failure is the cause of death in <20% of heart transplant patients 5 years after transplantation. 1 Therefore, decisions on ECCT listing are appropriately based primarily on recipient risk factors. In addition, our analysis suggests careful attention to immunosuppressive regimens in older ECCT recipients who may experience a greater number of adverse effects associated with these agents (ie, infection, malignancy, and renal failure). We currently do not withhold induction therapy from ECCT recipients and have similar maintenance regimens for all patients transplanted at our center. Our results suggest that a more personalized approach to immunosuppression in this high-risk cohort may further improve outcomes.
These results highlight the clinical trade-off that must be considered when determining treatment strategies for the patient with end-stage HF. In the current era, OHT provides the best long-term survival, especially for patients eligible for SCCT. 1 Although ECCT patients experience reduced survival and considerable long-term morbidity associated with renal dysfunction, there is little data to suggest that continued medical therapy without OHT provides a reasonable alternative. Alternative surgical strategies for patients ineligible for SCCT such as LVAD continue to demonstrate improved outcomes in the context of clinical trials 21 and postmarket analyses. Recent analyses suggest survival rates with destination therapy LVAD in excess of 60% at 2 years. 22 These rates may improve with LVAD use in patients who are less sick and not in critical cardiogenic shock at the time surgery, and this hypothesis is being tested in ongoing clinical trials. The survival, quality of life, and adverse event data from these studies will provide further insight into the appropriate use of transplantation and durable mechanical circulatory support in patients ineligible for SCCT. However, long-term follow-up data with contemporary assist devices will not be available for several years, and there have been few comparisons of ECCT with destination therapy LVAD. 23 Our results suggest that ECCT continues to have an important role in providing treatment options for a growing population of patients with end-stage HF. Optimal outcomes can be achieved with this strategy with careful patient selection based on common clinical variables such as renal function. Furthermore, significant post-transplant morbidity may be related to the toxic effects of chronic immunosuppression, and careful attention should be paid to tailoring immunosuppressive medications for this older population.
Limitations
Our study has several important limitations. This is a retrospective review of a single-center experience using ECCT that focuses on recipient rather than donor characteristics. We chose to disregard individual donor factors in the multivariable models to prevent overfitting, and therefore, we were unable to control for donor-specific factors that affect outcomes. In an attempt to correct for this, our analysis was built to determine the effects of recipient factors on survival as well as to define the additional risk associated with ECCT listing once recipient features are accounted for. Finally, as a result of inconsistencies and missing medical records, we are not able to report recipient cause of death accurately and reliably.
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